Caprico Biotechnologies

TECHNICAL DATA SHEET

BCMA (22625B)

Type	Size	Catalog Number
Unconjugated	100 µg	135001
	500 µg	135003
PE	25 Tests	135024
	100 Tests	135025
	200 Tests	135026
PE-Cyanine5	25 Tests	135074
	100 Tests	135075
	200 Tests	135076
PE-Cyanine7	25 Tests	135084
	100 Tests	135085
	200 Tests	135086
PE-CF594	25 Tests	1350204
	100 Tests	1350205
	200 Tests	1350206

Alternative name: CD269
Antigen: BCMA (B cell maturation antigen)
Immunogen: BCMA recombinant protein
Host/Isotype: Mouse, IgG1, κ
Reactivity: Human
Purity: >90% pure tested via polyacrylamide gel electrophoresis (PAGE)
Formulation: PBS, pH7.2, 0.09% NaN_3 and 0.1% (w/v) BSA (unconjugated)
PBS, pH7.2, 0.09% NaN_3 and 0.2% (w/v) BSA (conjugated)
Storage: Store at 2-8°C and protected from prolonged exposure to light. **Do not freeze.**
Applications: Flow Cytometry

Application Information

Each lot of these antibodies has been pre-titrated and tested by flow cytometric analysis of Human Multiple Myeloma cell line U266 such that 0.5µg (unconjugated) or 5µL (conjugated) of these products are sufficient for staining 1 million cells in a 100µL staining volume. It is recommended to titrate antibody reactivity empirically for optimal performance.

Antigen Information

BCMA (B cell maturation antigen), also known as CD269, is a ~27 kDa type III transmembrane glycoprotein encoded by the TNFRSF17 gene. It features a single TNFR-Cys repeat in its extracellular domain, followed by a transmembrane segment and a cytoplasmic tail that interacts with TRAF family proteins. CD269 is primarily expressed as a homotrimer on germinal center B cells, plasmablasts, and plasma cells, where it plays a critical role in the survival and maintenance of long-lived plasma cells.Its ligands, BAFF (CD257) and APRIL (CD256), activate intracellular signaling pathways essential for B cell maturation. CD269 is notably overexpressed in B cell malignancies, especially in multiple myeloma, and is implicated in autoimmune conditions such as systemic lupus erythematosus. Additionally, a soluble form of BCMA, produced by γ-secretase cleavage, can act as a decoy receptor to modulate the availability and signaling of its ligands, thereby influencing plasma cell differentiation and survival.

References

1. *Den Hartog G, et al. 2018. Eur J Immunol. 48:283.*

2. *Chen J, et al. 2020. Genome Biol. 0.980555556.*
3. *Metelo AM, et al. 2022. Cancer Res Commun. 2:158.*
4. *Ferguson ID, et al. 2022. Nat Commun. 13:4121.*
5. *Montes de Oca R, et al. 2021. Mol Cancer Ther. 20:1941.*
6. *Zah E, et al. 2020. Nat Commun. 11:2283.*
7. *Klein D, et al. 2021. Mol Ther. 29:2053.*

Terms and Conditions

This product is for research use only (RUO) and not intended for diagnostic testing.